Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar

The therapy could treat an underlying disease but is very early in development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.